Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain
Q4 Sales Edge Past Consensus
Executive Summary
Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.
You may also be interested in...
Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.
Novo Nordisk Named And Shamed For Paying Pharmacists To Boost Weight Loss Drug Sales
The company has been publicly reprimanded for its training program for UK pharmacists, which the industry watchdog judged to be solely focused on increasing use of weight loss drug Saxenda